



Jon Stoessl, CM, MD, is Professor and Acting Head of the Division of Neurology at the University of British Columbia & Vancouver Coastal Health. He also is Director, Pacific Parkinson's Research Centre and National Parkinson Foundation Centre of Excellence at the University of British Columbia. He has held the position of Canada Research Chair (Tier I) in Parkinson's Disease since 2000 and Director, CIHR Team in Parkinson's Disease since 2001. He also serves on the MSFHR Research Unit in Parkinson's Disease and Monoaminergic Function in the Central Nervous System. He has had many honors including becoming a member of the Order of Canada in 2007 and Fellow of the American Academy of Neurology and the Canadian Academy of Health Sciences. Dr. Stoessl is on the Scientific Advisory Board of the National Parkinson Foundation and recently completed chairing the Scientific Advisory Board of the Parkinson Society of Canada. He is on the editorial board of the *Annals of Neurology*, *Lancet Neurology* and *Parkinsonism & Related Disorders*. He serves on the World Federation of Neurology Research Committee on Parkinsonism & Related Disorders, Movement Disorders Society Awards Committee and International Executive Committee, and the Interdisciplinary Advisory Committee, Canada Research Chairs program. He currently serves as Co-chair of the PSG Mentoring Committee.

Representative Publications: (of >200 papers & book chapters)

Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente R, Calne DB, **Stoessl AJ** (2000). *In vivo* PET evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. *Ann. Neurol.* 47: 493-503.

de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, **Stoessl AJ** (2001). Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease. *Science* 293: 1164-1166.

Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, Strongosky A, Sossi V, Ruth TJ, Lee CS, Farrer M, Gasser T, Uitti RJ, Calne DB, Wszolek ZK, **Stoessl AJ** (2005). PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. *Brain* 128:2777-85.

Nandhagopal R, Mak E, Schulzer M, McKenzie J, McCormick S, Sossi V, Ruth TJ, Strongosky A, Farrer MJ, Wszolek ZK, **Stoessl AJ** (2008). Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. *Neurology* 71: 1790-1795.

Troiano AR, de la Fuente-Fernandez R, Sossi V, Schulzer M, Mak E, Ruth TJ, **Stoessl AJ** (2009). PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. *Neurology* 72: 1211-1216.

Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, Lee CS, McKenzie J, McCormick S, Samii A, Troiano A, Ruth TJ, Sossi V, de la Fuente-Fernandez R, Calne DB, **Stoessl AJ** (2009). Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. *Brain* (available online).